Jeremy T Booth1, Vincent Caillet2, Nicholas Hardcastle3, Ricky O'Brien4, Kathryn Szymura5, Charlene Crasta5, Benjamin Harris5, Carol Haddad5, Thomas Eade5, Paul J Keall4. 1. Northern Sydney Cancer Centre, Level 1 Royal North Shore Hospital, Sydney, Australia; University of Sydney, Schools of Physics or Medicine, Sydney, Australia. Electronic address: Jeremy.Booth@health.nsw.gov.au. 2. Northern Sydney Cancer Centre, Level 1 Royal North Shore Hospital, Sydney, Australia; University of Sydney, Schools of Physics or Medicine, Sydney, Australia. 3. Northern Sydney Cancer Centre, Level 1 Royal North Shore Hospital, Sydney, Australia; Centre for Medical Radiation Physics, University of Wollongong, Wollongong, Australia. 4. University of Sydney, Schools of Physics or Medicine, Sydney, Australia. 5. Northern Sydney Cancer Centre, Level 1 Royal North Shore Hospital, Sydney, Australia.
Abstract
BACKGROUND AND PURPOSE: Real time adaptive radiotherapy that enables smaller irradiated volumes may reduce pulmonary toxicity. We report on the first patient treatment of electromagnetic-guided real time adaptive radiotherapy delivered with MLC tracking for lung stereotactic ablative body radiotherapy. MATERIALS AND METHODS: A clinical trial was developed to investigate the safety and feasibility of MLC tracking in lung. The first patient was an 80-year old man with a single left lower lobe lung metastasis to be treated with SABR to 48Gy in 4 fractions. In-house software was integrated with a standard linear accelerator to adapt the treatment beam shape and position based on electromagnetic transponders implanted in the lung. MLC tracking plans were compared against standard ITV-based treatment planning. MLC tracking plan delivery was reconstructed in the patient to confirm safe delivery. RESULTS: Real time adaptive radiotherapy delivered with MLC tracking compared to standard ITV-based planning reduced the PTV by 41% (18.7-11cm3) and the mean lung dose by 30% (202-140cGy), V20 by 35% (2.6-1.5%) and V5 by 9% (8.9-8%). CONCLUSION: An emerging technology, MLC tracking, has been translated into the clinic and used to treat lung SABR patients for the first time. This milestone represents an important first step for clinical real-time adaptive radiotherapy that could reduce pulmonary toxicity in lung radiotherapy.
BACKGROUND AND PURPOSE: Real time adaptive radiotherapy that enables smaller irradiated volumes may reduce pulmonary toxicity. We report on the first patient treatment of electromagnetic-guided real time adaptive radiotherapy delivered with MLC tracking for lung stereotactic ablative body radiotherapy. MATERIALS AND METHODS: A clinical trial was developed to investigate the safety and feasibility of MLC tracking in lung. The first patient was an 80-year old man with a single left lower lobe lung metastasis to be treated with SABR to 48Gy in 4 fractions. In-house software was integrated with a standard linear accelerator to adapt the treatment beam shape and position based on electromagnetic transponders implanted in the lung. MLC tracking plans were compared against standard ITV-based treatment planning. MLC tracking plan delivery was reconstructed in the patient to confirm safe delivery. RESULTS: Real time adaptive radiotherapy delivered with MLC tracking compared to standard ITV-based planning reduced the PTV by 41% (18.7-11cm3) and the mean lung dose by 30% (202-140cGy), V20 by 35% (2.6-1.5%) and V5 by 9% (8.9-8%). CONCLUSION: An emerging technology, MLC tracking, has been translated into the clinic and used to treat lung SABRpatients for the first time. This milestone represents an important first step for clinical real-time adaptive radiotherapy that could reduce pulmonary toxicity in lung radiotherapy.
Authors: Maksat Haytmyradov; Rakesh Patel; Hassan Mostafavi; Murat Surucu; Adam Wang; Matthew M Harkenrider; John C Roeske Journal: Phys Med Biol Date: 2019-01-21 Impact factor: 3.609
Authors: Kevin C Jones; Julius Turian; Gage Redler; Gizem Cifter; John Strologas; Alistair Templeton; Damian Bernard; James C H Chu Journal: Phys Med Biol Date: 2020-08-10 Impact factor: 3.609
Authors: Paul J Keall; Doan Trang Nguyen; Ricky O'Brien; Pengpeng Zhang; Laura Happersett; Jenny Bertholet; Per R Poulsen Journal: Int J Radiat Oncol Biol Phys Date: 2018-04-14 Impact factor: 7.038
Authors: Chun-Chien Shieh; Vincent Caillet; Michelle Dunbar; Paul J Keall; Jeremy T Booth; Nicholas Hardcastle; Carol Haddad; Thomas Eade; Ilana Feain Journal: Phys Med Biol Date: 2017-03-21 Impact factor: 3.609
Authors: Marco Mueller; Per Poulsen; Rune Hansen; Wilko Verbakel; Ross Berbeco; Dianne Ferguson; Shinichiro Mori; Lei Ren; John C Roeske; Lei Wang; Pengpeng Zhang; Paul Keall Journal: Med Phys Date: 2021-12-29 Impact factor: 4.071
Authors: Maksat Haytmyradov; Hassan Mostafavi; Adam Wang; Liangjia Zhu; Murat Surucu; Rakesh Patel; Arun Ganguly; Michelle Richmond; Roberto Cassetta; Matthew M Harkenrider; John C Roeske Journal: Med Phys Date: 2019-06-01 Impact factor: 4.071